论文部分内容阅读
Phase Ⅱa trial of chimeric antigen receptor modified T cells directed against CD19 (CTL019) in patie
【作 者】
:
【机 构】
:
Abramson Cancer Center, University of Pennsylvania, Philadelphia, PA
【出 处】
:
2015年临床肿瘤学新进展学术研讨会
【发表日期】
:
2015年3期
其他文献
会议
A pharmacokinetically (PK) and pharmacodynamically (PD) driven phase I trial of the pan-AKT inhibito
会议
会议
Efficacy based on tumor PD-L1 expression in KEYNOTE-002, a randomized comparison of pembrolizumab (p
会议
GADOLIN: Primary results from a phase Ⅲ study of obinutuzumab plus bendamustine compared with bendam
会议